Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
Popat R, Oriol A, Cavo M, Karlin L, Mazza I, Roeloffzen W, Kim S, Lipe B, Bar N, Horvath N, Spencer A, Min C, Chen D, Li Q, Li K, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Lendvai N, Lengil T, Patel N, Filho O, Florendo E, Lin Y. Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial. Blood 2024, 144: 1032. DOI: 10.1182/blood-2024-201533.Peer-Reviewed Original ResearchMinimal residual disease negativityMRD-negativity ratesSustained MRD negativityMinimal residual diseaseProgression-free survivalMedian progression-free survivalCilta-celMRD negativitySOC armOverall survivalMultiple myelomaInterim analysisPost-infusionFollow-upMinimal residual disease assessmentMinimal residual disease dataMinimal residual disease positivityCilta-cel infusionProlonged survival outcomesMedian follow-upOverall response rateNegative resultsStandard of careMedian OSComplete responseLong-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
Bar N, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, De Champlain A, Gries K, Chen D, Li Q, Yeh T, Slaughter A, Lonardi C, Benachour N, Ghosh A, Deraedt W, Vogel M, Lendvai N, Patel N, Costa Filho O, Florendo E, Karlin L, Weisel K. Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial. Blood 2024, 144: 2002-2002. DOI: 10.1182/blood-2024-209232.Peer-Reviewed Original ResearchProgression-free survivalAnti-myeloma therapyLenalidomide-refractory multiple myelomaCilta-celMedian follow-upFollow-upMultiple myelomaStandard of careCiltacabtagene autoleucelProgressive diseaseMedian timeSOC armRefractory to lenalidomideYears of follow-upAnti-myeloma treatmentKaplan-Meier methodData cut-offCox proportional hazards modelsConfidence intervalsWorsening of symptomsRisk of deathProportional hazards modelFunctional impactEuropean Organization for ResearchMM patients